4:48 PM
 | 
Oct 15, 2018
 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN). He replaces Fred Fideorek, who left Rhythm over the summer to join Intarcia Therapeutics Inc. (Boston, Mass.) as CMO and global head of regulatory affairs.

Neurology company Redpin Therapeutics Inc. (New York City, N.Y.) hired David Bleakman as CSO. Bleakman was VP, CSO and neuroscience site leader, New York, at Eli Lilly and Co. (NYSE:LLY). Founded in 2017, Redpin is...

Read the full 453 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >